Spanish drugmaker Grifols SA said Monday that it reached an agreement with regulators regarding its planned acquisition of Talecris Biotherapeutics Holdings Corp., and will sell some of Talecris' assets.
Grifols said the staff of the Federal Trade Commission's bureau of competition approved a plan under which Grifols would sell the U.S. assets of Talecris' hemophilia treatment Koate, two plasma collection centers and a facility in Melville, N.Y. The proposed buyer is Kendrion, an Italian company. Grifols also agreed to purify blood plasma for Kendrion and deliver Koate, intravenous immunoglobulin and albumin under Kendrion's private label.
The agreements would last up to seven years.
The proposal has not been cleared by the FTC's commissioners. If the FTC clears the deal, Grifols would take a significant step toward closing its $3.4 billion deal for Talecris. Grifols agreed to buy the Research Triangle Park, N.C., company in June, and Talecris shareholders have approved the deal. The offer values Talecris at $26.16 per share in cash and stock.
Talecris shares rose 87 cents, or 3.1 percent, to $28.79 in Monday trading.